CN107997174B - Health composition and health food with sleep improving and/or antidepressant effects - Google Patents
Health composition and health food with sleep improving and/or antidepressant effects Download PDFInfo
- Publication number
- CN107997174B CN107997174B CN201711336886.7A CN201711336886A CN107997174B CN 107997174 B CN107997174 B CN 107997174B CN 201711336886 A CN201711336886 A CN 201711336886A CN 107997174 B CN107997174 B CN 107997174B
- Authority
- CN
- China
- Prior art keywords
- parts
- health
- weight
- extract
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000007958 sleep Effects 0.000 title claims abstract description 26
- 235000013402 health food Nutrition 0.000 title claims description 19
- 230000036541 health Effects 0.000 title claims description 15
- 230000001430 anti-depressive effect Effects 0.000 title claims description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 46
- 229940026510 theanine Drugs 0.000 claims abstract description 25
- 241000096284 Gynochthodes officinalis Species 0.000 claims abstract description 24
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 22
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229960004977 anhydrous lactose Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 65
- 241001465754 Metazoa Species 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 241000700159 Rattus Species 0.000 description 21
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 21
- 229960001412 pentobarbital Drugs 0.000 description 19
- 230000004622 sleep time Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 229960002275 pentobarbital sodium Drugs 0.000 description 7
- 230000028527 righting reflex Effects 0.000 description 7
- 230000004620 sleep latency Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 229960000796 barbital sodium Drugs 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000000517 effect on sleep Effects 0.000 description 2
- 238000012048 forced swim test Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001120455 Angelica furcijuga Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 235000011515 Angelica tenuisecta var furcijuga Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000717662 Clinopodium chinense Species 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241000308663 Eupatorium fortunei Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 241000737253 Lygodium japonicum Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001229135 Nassa Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241000244271 Pleurospermum Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of health-care food, in particular to a health-care composition and health-care food with sleep improving and/or anti-depression effects. The health-care composition is prepared from 1-20 parts by weight of GABA-aminobutyric acid, 1-30 parts by weight of theanine, 1-50 parts by weight of rhizoma gastrodiae extract and 1-80 parts by weight of morinda officinalis extract. The invention has the technical effects that: the health-care composition has obvious synergistic effect on the aspects of improving sleep and/or resisting depression after the GABA-aminobutyric acid, the theanine, the gastrodia elata extract and the morinda officinalis extract are used in a matched manner.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a health-care composition and health-care food with sleep improving and/or anti-depression effects.
Background
Depression, also known as depressive disorder, is characterized clinically by a marked and persistent depression in the mood, the main type of mood disorder. The low mood is not matched with the situation in clinic, the depression of the mood can be from sultriness to sadness, and the self-declining depression and even the pessimism are taken away, and suicide attempts or behaviors can be caused; even the occurrence of stupor; in some cases, there is significant anxiety and motor agitation; in severe cases, psychotic symptoms such as hallucinations and delusions may occur. The physical symptoms mainly comprise sleep disorder, hypodynamia, anorexia, weight loss, constipation, pain of any part of the body, hyposexuality, impotence, amenorrhea and the like. The sleep disorder is mainly manifested by early awakening, generally awakening for 2-3 hours earlier than usual, and can not fall asleep after awakening, which has characteristic significance for depressive episode.
Drug therapy is the primary treatment for depression episodes above moderate. The first-line antidepressants currently in clinical use mainly include selective 5-hydroxytryptamine reuptake inhibitors (SSRI, which stands for the drugs fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram and escitalopram), 5-hydroxytryptamine and norepinephrine reuptake inhibitors (SNRI, which stands for the drugs venlafaxine and duloxetine), norepinephrine and specific 5-hydroxytryptamine antidepressants (NaSSA, which stands for the drug mirtazapine), etc. The traditional tricyclic and tetracyclic antidepressants and monoamine oxidase inhibitors have larger adverse reactions and obviously reduced application.
GABA (gamma-aminobutyric acid) is a naturally-occurring non-protein functional amino acid, a natural active ingredient, is a main inhibitory neurotransmitter of the central nervous system and mediates the rapid inhibition of the nervous system, and gamma-aminobutyric acid is an important inhibitory neurotransmitter which is deeply researched and participates in various metabolic activities and has high physiological activity. Can be used for treating hepatic coma and brain metabolism disorder, and relieving restlessness, and is a pure natural substance for resisting depression and anxiety, improving mood, relieving stress, promoting sleep, improving brain activity, removing toxic substance and relieving hangover.
Theanine (L-Theanine) is a free amino acid peculiar to tea leaves, and is glutamic acid gamma-ethylamide, and has sweet taste. Theanine is similar to active matters in brain, namely glutamine and glutamic acid in chemical structure, and is a main component for promoting the secretion of body fluid and moistening and sweetening tea. Theanine can relieve fatigue, lower blood pressure and improve learning and memory ability.
Gastrodia elata Bl, also known as Thymus chinensis, Pleurospermum, Lygodium japonicum, Angelica furcijuga, Eupatorium fortunei, Gastrodia elata, Angelica sinensis, Pop, Gastrodia elata, Clinopodium chinense, white dragon skin, and the like, is a perennial herb of Gastrodia genus of Orchidaceae. The rhizome of the Chinese medicinal composition is used for treating dizziness, numbness of limbs, infantile convulsion and other symptoms, is a rare Chinese medicament, and is used together with Qiongzhen lucid ganoderma for treating headache and insomnia.
Morinda officinalis (scientific name: Morinda officinalis How) is a dicotyledonous plant of Rubiaceae, mainly produced in Guangdong, Guangxi, etc. The medicinal plants are mainly used for treating impotence, spermatorrhea, infertility due to cold womb, irregular menstruation, cold pain in lower abdomen, rheumatic arthralgia, and flaccidity of bones and muscles.
At present, no report on the combined use of GABA-aminobutyric acid, theanine, a gastrodia elata extract and a morinda officinalis extract is found.
Disclosure of Invention
In view of the above, the present invention provides a health composition and a health food having sleep improving and/or antidepressant effects. The health-care composition has remarkable synergistic effect on the aspects of improving sleep and/or resisting depression after GABA-aminobutyric acid, theanine, the gastrodia elata extract and the morinda officinalis extract are used in a matched mode.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a health-care composition which is prepared from 1-20 parts by weight of GABA-aminobutyric acid, 1-30 parts by weight of theanine, 1-50 parts by weight of rhizoma gastrodiae extract and 1-80 parts by weight of morinda officinalis extract.
Preferably, the health care composition is prepared from 5-10 parts by weight of GABA-aminobutyric acid, 5-25 parts by weight of theanine, 10-35 parts by weight of rhizoma gastrodiae extract and 30-60 parts by weight of morinda officinalis extract.
In a specific embodiment provided by the present invention, the health composition is prepared from, by weight, 5 parts of GABA-aminobutyric acid, 25 parts of theanine, 30 parts of gastrodia elata extract and 40 parts of morinda officinalis extract.
In another embodiment provided by the present invention, the health composition is prepared from 10 parts by weight of GABA-aminobutyric acid, 25 parts by weight of theanine, 35 parts by weight of gastrodia elata extract and 30 parts by weight of morinda officinalis extract.
In another embodiment provided by the present invention, the health composition is prepared from 10 parts by weight of GABA-aminobutyric acid, 20 parts by weight of theanine, 10 parts by weight of gastrodia elata extract and 60 parts by weight of morinda officinalis extract.
In another embodiment provided by the present invention, the health composition is prepared from 5 parts by weight of GABA-aminobutyric acid, 5 parts by weight of theanine, 30 parts by weight of gastrodia elata extract and 60 parts by weight of morinda officinalis extract.
The invention also provides application of the health-care composition in preparing health-care food for improving sleep and/or resisting depression.
The invention also provides a health food which comprises the health composition provided by the invention.
Preferably, the health food is in the form of capsule, tablet, powder or granule.
Preferably, the health food is in the form of capsules, and the raw materials of the health food comprise: 1-10 parts of GABA-aminobutyric acid, 5-20 parts of theanine, 10-30 parts of rhizoma gastrodiae extract, 10-30 parts of morinda officinalis extract, 10-30 parts of pregelatinized starch, 5-10 parts of croscarmellose sodium and 1-5 parts of magnesium stearate.
Preferably, the health food is in the form of tablets, and the raw materials of the health food comprise: 1-10 parts of GABA-aminobutyric acid, 5-20 parts of theanine, 10-30 parts of rhizoma gastrodiae extract, 10-30 parts of morinda officinalis extract, 10-15 parts of microcrystalline cellulose, 5-10 parts of anhydrous lactose, 1-5 parts of croscarmellose sodium, 1-5 parts of silicon dioxide, 1-2 parts of magnesium stearate and 0.5-1 part of brown film coating powder.
The invention provides a health-care composition and health-care food with sleep improving and/or anti-depression effects. The health-care composition is prepared from 1-20 parts by weight of GABA-aminobutyric acid, 1-30 parts by weight of theanine, 1-50 parts by weight of rhizoma gastrodiae extract and 1-80 parts by weight of morinda officinalis extract. The invention has the technical effects that: the health-care composition has obvious synergistic effect on the aspects of improving sleep and/or resisting depression after the GABA-aminobutyric acid, the theanine, the gastrodia elata extract and the morinda officinalis extract are used in a matched manner.
Detailed Description
The invention discloses a health-care composition and health-care food with sleep improvement and/or anti-depression effects, which can be realized by appropriately improving process parameters by taking the contents into consideration by the technical personnel in the field. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The raw materials or auxiliary materials used in the health-care composition and the health-care food with the effects of improving sleep and/or resisting depression provided by the invention can be purchased from the market. The extracts of rhizoma Gastrodiae and radix Morindae officinalis are water extracts, and the extraction method is well known to those skilled in the art.
The invention is further illustrated by the following examples:
test example 1
(one) test for improving depressed animals
1.1 Experimental animals
Selecting SPF male SD rats with the weight of 180 +/-10 g, purchasing the animals from Guangdong province medical experimental animal center, and using license numbers of the experimental animals: SYXK (Yue) 2013-.
1.2 Experimental groups
SD strain male rat 110, body weight 200 g. Training animals to adapt to sugar water before the test, and layering according to the preference degree of the sugar water, so that the preference degree of rats in each group is distributed evenly. The experiments were divided into 11 groups, each: a normal control group, a model group, a positive control group citalopram group, a first control group, a second control group, a third control group, a fourth control group, a first test group, a second test group, a third test group and a fourth test group, wherein each group comprises 10 animals.
Table 1 test each group of administered ingredients
TABLE 2 administration component ratio of control group and test group
1.3 test methods
Rats in the normal control group were placed in another room, 5 rats/cage, and fed normally at the same room temperature and under the same light conditions, without stimulation except fasting and water deprivation before the sugar water preference test and forced swimming test. Except for a normal control group, the depression model is prepared by adopting a Chronic Unpredictable Mild Stimulation (CUMS) and isolated feeding mode in other groups. The CUMS specific method is as follows: fasting and water prohibition are carried out for 24 h/time, 4-degree water swimming is carried out for 5 min/time, padding is moistened for 8 h/time, a binding cage is bound for 2 h/time, the tail of a hemostatic forceps is clamped for 1 min/time, 36V electrical stimulation is carried out for 1min and is separated for 30s for 30 cycles/time, and 3 kinds of stress are given every day according to a random digital table. The test sample intervention was carried out starting from 8 weeks of age of the rats after 4 weeks of continuous stimulation, and continued until the end of the whole experiment.
1.4 detection index
1) Sugar water preference test (pre-intervention, intervention 15d, intervention 30 d):
after fasting and water deprivation for 24h, weighing, simultaneously giving 1 bottle of 2% sucrose water 100mL and 1 bottle of 100mL pure water to each animal, observing the amount of sucrose solution drunk by the animals within 1h, calculating the sugar water preference degree, and comparing whether the sugar water preference degrees of each group have difference:
preference level (sugar water consumption/total liquid consumption) × 100%.
2) Forced swimming test (before intervention, intervention 15d, intervention 30d)
A transparent cylindrical swimming cylinder with the height of 45cm, the diameter of 20cm and the water temperature of 25 ℃ is used for detecting the time required by a rat from the beginning of swimming to the stationary state. The time required for each group was compared for differences.
1.5 data statistics method
Data mining
Statistical analysis was performed using SPSS21.0 software. If the measured data are uniform in variance or uniform in variance after conversion, adopting one-factor variance analysis, comparing among groups by using an LSD method, if the variance is not uniform, and if the data are not uniform after conversion, adopting rank sum test to carry out statistical analysis. The assay level α is 0.05.
1.6 results and analysis
1.6.1 Effect of chronic moderate unpredictable stress on sugar water consumption in rats:
compared with the blank group, the sugar water consumption of the rats in the model group is obviously reduced and has statistical difference (P <0.01), which indicates that the model group is successfully modeled, and compared with the model group, the sugar water consumption of the rats in the positive group, the rats in the control 1 group and the rats in the control 2 group are also obviously increased, the sugar water consumption of the rats in the test group has statistical difference (P <0.01 or P <0.05), and the sugar water consumption of the rats in the test group has statistical difference (P < 0.01). The test group is proved to have the function of increasing the sugar water consumption.
TABLE 3 Effect of chronic moderate unpredictable stress on sugar water consumption in rats
| Group of | Number of animals | Consumption of syrup (%) |
| Blank group | 10 | 75.50±9.35 |
| Model set | 10 | 27.63±5.71▲▲ |
| Positive group | 10 | 47.50±9.35** |
| Control 1 group | 10 | 30.10±3.87 |
| Control 2 group | 10 | 28.27±4.56 |
| Control 3 group | 10 | 26.79±4.93 |
| Control 4 group | 10 | 30.12±5.78 |
| Test 1 group | 10 | 35.00±7.29* |
| Test 2 groups | 10 | 38.13±6.64* |
| Test 3 groups | 10 | 42.68±5.89** |
| Test 4 groups | 10 | 45.32±3.76** |
Note: compared with the blank control group, the composition of the composition,▲P<0.05，▲▲P<0.01; comparison with model group<0.05，**P<0.01。
1.6.2 Effect of Chronic moderate unpredictable stress on immobility time in forced swim tests
Compared with the blank group, the rat in the model group has obviously prolonged forced swimming immobility time and statistical difference (P <0.05), which indicates that the model building is successful. Compared with the model group, the forced swimming immobility time of the rats in the positive group is obviously shortened, and the statistical difference is realized (P < 0.05); the rats in the control group 1 and the control group 2 have a tendency of shortening forced swimming, but have no statistical difference (P is more than 0.05), the forced swimming immobility time of the rats in the test group is obviously shortened, and the rats have a statistical difference (P is less than 0.05), which indicates that the test group can improve the forced swimming test immobility time of the rats caused by chronic moderate unpredictable stress.
TABLE 4 Effect of chronic moderate unpredictable stress on immobility time in forced swim tests
| Group of | Number of animals | Immobility time (seconds) |
| Blank group | 10 | 85.13±12.79 |
| Model set | 10 | 123.50±18.54▲▲ |
| Positive control group | 10 | 98.63±11.49* |
| Control 1 group | 10 | 109.13±11.95 |
| Control 2 group | 10 | 108.25±10.82 |
| Control 3 group | 10 | 114.13±15.44 |
| Control 4 group | 10 | 112.88±13.30 |
| Test 1 group | 10 | 102.75±17.29* |
| Test 2 groups | 10 | 104.00±16.59* |
| Test 3 groups | 10 | 102.75±12.50* |
| Test 4 groups | 10 | 100.75±12.17* |
Note: compared with the blank control group, the composition of the composition,▲P<0.05，▲▲P<0.01; comparison with model group<0.05，**P<0.01。
(II) test for improving sleep
1.1 Experimental animals
SPF level thorny ICR mice are selected, the weight is 20 +/-2 g, the animals are purchased from the centers of medical experimental animals in Guangdong province, and the experimental animals use license numbers: SYXK (Yue) 2013-.
1.2 Experimental groups
Refer to the method in "technical Specification for testing and evaluating health food" (2003 edition). Healthy female ICR mice with the weight of 18 g-22 g and 120 mice are divided into 3 batches for experiments, the 1 st batch of animals are used for direct sleep experiments and experiments for prolonging the sleep time of pentobarbital sodium, the 2 nd batch of animals are used for subthreshold dose hypnosis experiments of pentobarbital sodium, and the 3 rd batch of animals are used for sleep latency experiments of the pentobarbital sodium.
The experiment was divided into 9 groups of 20 animals each, respectively: the blank group, the control 1 group, the control 2 group, the control 3 group, the control 4 group, the test 1 group, the test 2 group, the test 3 group and the test 4 group were subjected to oral gavage at 0.2mL/10 g.BW, and the negative control group was administered with an equal amount of solvent and was gavaged 1 time per day.
Table 5 test of the administered ingredients of each group
TABLE 6 administration component ratio of control group and test group
1.3 test methods
The method was carried out according to the "technical Specification for testing and evaluating health foods" (2003 edition) of the Ministry of health. The experiment was set up in 3 sections: an experiment for prolonging the sleep time of the sodium pentobarbital, an experiment for hypnotizing the sodium pentobarbital at a subthreshold dose and an experiment for the sleep latency of the sodium pentobarbital.
1.3.1 direct sleep experiment: and observing whether the sleeping phenomenon appears after the negative control group is added with the solvent with the same volume after the animals of the test group are added with the test sample. The disappearance of the righting reflex is used as an index for sleeping. If the patient can not be righted for more than 30-60 s, the righting reflex is considered to disappear, and the patient enters sleep. The recovery of the righting reflex is arousal, and the time from disappearance of the righting reflex to recovery is the sleeping time of the animal. The number of animals falling asleep and the sleeping time of the control group and the test sample group were recorded.
1.3.2 experiment for prolonging sleep time of sodium pentobarbital: if the direct sleep experiment is negative, an experiment for prolonging the sleep time of the sodium pentobarbital is carried out. Before the formal experiment, the preliminary experiment is carried out, the dose of the sodium pentobarbital which enables the animals to fall asleep for 100 percent but does not lead to overlong sleep time is determined, and the formal experiment is carried out by using the dose (the experiment dose is 47mg/kg BW). And (3) after the animals are given the solvent and the tested samples with different concentrations for the last time, injecting the sodium pentobarbital into the abdominal cavity of each group of animals 10-15 min before the peak effect appears, and observing whether the tested samples can prolong the sleep time of the sodium pentobarbital by taking the disappearance of the righting reflex as an index.
1.3.3 sub-threshold dose hypnotic assay of sodium pentobarbital: a pre-experiment is carried out before a formal experiment is carried out, and the sub-threshold hypnotic dose of the sodium pentobarbital, namely the maximum sub-threshold dose of the sodium pentobarbital of which 80-90 percent of mouse righting reflex does not disappear, is determined. After animals are given solvent and test samples with different concentrations in the last time, 10 min-15 min before peak effect appears, the maximum sub-threshold hypnotic dose of the sodium pentobarbital (the experimental dose is 29mg/kg BW) is injected into the abdominal cavity of each group of animals, and the number of the animals falling asleep within 30min (the number of the animals with turning positive reflex disappears for more than 1 min) is recorded.
1.3.4 pentobarbital sodium sleep latency experiments: before formal experiments, the prior experiments are carried out, the dosage of the barbital sodium which enables the animals to fall asleep for 100 percent but does not lead to overlong sleep time is determined, and the formal experiments are carried out by using the dosage. After animals are given solvent and tested samples with different concentrations for 10-20 min in the last time, the animals are injected with barbital sodium (the experimental dosage is 240 mg/kg. BW) into the abdominal cavity of each group of animals, the influence of the tested samples on the sleep latency of the barbital sodium is observed by taking the disappearance of righting reflex as an index.
1.4 judging the result:
the test for prolonging the sleep time of the pentobarbital sodium, the test for hypnotizing the pentobarbital sodium (or the barbital sodium) at the subthreshold dose and the test for the sleep latency of the barbital sodium have two positive tests without obvious direct sleep effect, and the test sample can be judged to have the function of improving the sleep.
1.5 statistical methods
Data were statistically analyzed using SPSS 17.0. The sleep time is measured data, the data is counted by analysis of variance, the non-normal or non-uniform variance data is subjected to proper variable conversion, and the converted data is used for counting after the requirements of normal or uniform variance are met; if the variable still does not reach the goal of being normal or uniform in variance after conversion, the statistics is carried out by using the rank sum test. The number of animals falling asleep is counted and tested by X2.
1.6 results and analysis
1.6.1 direct sleep experiment
After the test samples are given to each test group and the solvent with the same volume is given to the negative control group, the positive turning reflex exists and the sleep phenomenon does not appear after the observation for 30 min.
TABLE 7 Effect of samples on direct sleep testing
| Group of | Number of animals | Number of sleeping animals | Sleep rate (%) |
| Blank group | 20 | 0 | 0 |
| Control 1 group | 20 | 0 | 0 |
| Control 2 group | 20 | 0 | 0 |
| Control 3 group | 20 | 0 | 0 |
| Control 4 group | 20 | 0 | 0 |
| Test 1 group | 20 | 0 | 0 |
| Test 2 groups | 20 | 0 | 0 |
| Test 3 groups | 20 | 0 | 0 |
| Test 4 groups | 20 | 0 | 0 |
Note: the comparison of the blank control group is carried out,▲P<0.05，▲▲P<0.01。
1.6.2 test for prolonging sleep time of sodium pentobarbital
Compared with a blank control group, the average sleep time of the mice of the control group 1, the control group 2 and the test group is slightly prolonged, wherein the sleep time of the mice of the test group is obviously increased compared with the control group (P is less than 0.05), and the statistical significance is realized, namely the test group has a function of prolonging the average sleep time of the mice induced by pentobarbital.
TABLE 8 Effect of samples on prolonging sleep time of sodium pentobarbital
Note: the comparison of the blank control group is carried out,▲P<0.05，▲▲P<0.01。
1.6.3 Pentobarbital sodium subthreshold dose hypnotic test
Compared with the blank group, the sleep incidence rates of the mice in the control group 1, the control group 2 and the test group have no obvious change and have no statistical significance (P > 0.05), so the product has no obvious effect on the sleep incidence rate of the mice induced by the sub-threshold dose of pentobarbital.
TABLE 9 Effect of samples on the sub-threshold dose hypnotic test of sodium pentobarbital
Note: the comparison of the blank control group is carried out,▲P<0.05，▲▲P<0.01。
1.6.4 test for sleep latency period of sodium pentobarbital
Compared with the blank group, the average sleep time of the mice of the control group 1, the control group 2 and the test group is slightly prolonged, wherein the average sleep latency of the mice of the test group is obviously shortened (P <0.05) compared with the control group, and the statistical significance is realized.
TABLE 10 Effect on sleep latency time of sodium pentobarbital
Note: the comparison of the blank control group is carried out,▲P<0.05，▲▲P<0.01。
EXAMPLE 1 Capsule product formulation and Process
Firstly, the formula (in parts by weight):
secondly, the production process comprises the following steps:
1. weighing and preparing materials: weighing GABA-aminobutyric acid, theanine, a gastrodia elata extract, a morinda officinalis extract, pregelatinized starch, cross-linked sodium carboxymethylcellulose and magnesium stearate in the formula amount for later use.
2. Total mixing: and adding the prepared materials into a mixer, mixing for 30 minutes until the materials are uniformly mixed, and discharging.
3. Filling: adding the uniformly mixed materials into a capsule filling machine, filling the materials with No. 0 hollow capsules at a dose of 400 mg/capsule, controlling the filling amount within +/-4.5%, and enabling the disintegration time to be less than 60 minutes.
4. Bottling: the equipment is adjusted as required, and the capsules are filled in 150ml of brown, 60 granules/bottle and 1 bag of desiccant.
Thirdly, the eating amount and the eating method are as follows: it is administered orally with 150ml warm water 2 times daily, 2 bags each time.
EXAMPLE 2 tablet product formulation and Process
Firstly, the formula (in parts by weight):
secondly, the production process comprises the following steps:
1. weighing and preparing materials: weighing GABA-aminobutyric acid, theanine, rhizoma gastrodiae extract, morinda officinalis extract, microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, silicon dioxide, magnesium stearate and brown film coating powder (water-soluble) according to the prescription amount for later use.
2. Total mixing: adding the prepared materials (except the magnesium stearate and the brown film coating powder) into a mixer, mixing for 25 minutes, adding the magnesium stearate with the formula amount, mixing for 5 minutes, and discharging after the mixture is uniform.
3. Tabletting: tabletting with a long strip mold, 800 mg/tablet, hardness of 22-27kg/cm2Ensure that the weight variation of the tablets is within +/-4.5 percent, the disintegration time is less than 30 minutes, and the appearance of the tablets is checked at any time.
4. Coating: the weight of the coating is increased by 3.63% by coating with brown film coating powder (water-soluble), and the solid content is 16%.
5. Bottling: the equipment is adjusted as required, and the coated tablets are packed in 150ml brown, 60 tablets/bottle and 1 bag of drying agent.
Thirdly, the eating amount and the eating method are as follows: it is taken orally 2 times a day, 2 tablets each time.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (9)
1. A health-care composition is characterized by being prepared from 5-10 parts by weight of GABA-aminobutyric acid, 5-25 parts by weight of theanine, 10-35 parts by weight of gastrodia elata extract and 30-60 parts by weight of morinda officinalis extract.
2. The health composition of claim 1, comprising 5 parts by weight of GABA-aminobutyric acid, 25 parts by weight of theanine, 30 parts by weight of the extract of gastrodia elata, and 40 parts by weight of the extract of morinda officinalis.
3. The health composition of claim 1, comprising, in parts by weight, 10 parts GABA-aminobutyric acid, 25 parts theanine, 35 parts gastrodia elata extract, and 30 parts morinda officinalis extract.
4. The health composition of claim 1, comprising, in parts by weight, 10 parts GABA-aminobutyric acid, 20 parts theanine, 10 parts gastrodia elata extract, and 60 parts morinda officinalis extract.
5. Use of a health composition according to any one of claims 1 to 4 in the manufacture of a health food for improving sleep and/or aiding in antidepressant.
6. A health food comprising the health composition according to any one of claims 1 to 4.
7. The health food according to claim 6, wherein the health food is in the form of a capsule, a tablet, a powder or a granule.
8. The health food as claimed in claim 7, wherein the health food is in the form of capsule, and comprises the following raw materials: 1-10 parts of GABA-aminobutyric acid, 5-20 parts of theanine, 10-30 parts of rhizoma gastrodiae extract, 10-30 parts of morinda officinalis extract, 10-30 parts of pregelatinized starch, 5-10 parts of croscarmellose sodium and 1-5 parts of magnesium stearate.
9. The health food according to claim 7, wherein the health food is in the form of a tablet, and comprises the following raw materials: 1-10 parts of GABA-aminobutyric acid, 5-20 parts of theanine, 10-30 parts of rhizoma gastrodiae extract, 10-30 parts of morinda officinalis extract, 10-15 parts of microcrystalline cellulose, 5-10 parts of anhydrous lactose, 1-5 parts of croscarmellose sodium, 1-5 parts of silicon dioxide, 1-2 parts of magnesium stearate and 0.5-1 part of brown film coating powder.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711336886.7A CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
| PCT/CN2018/111880 WO2019114428A1 (en) | 2017-12-14 | 2018-10-25 | Health-care composition and health-care food having efficacy of improving sleep and/or resisting depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711336886.7A CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107997174A CN107997174A (en) | 2018-05-08 |
| CN107997174B true CN107997174B (en) | 2021-05-04 |
Family
ID=62058823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711336886.7A Active CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107997174B (en) |
| WO (1) | WO2019114428A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107997174B (en) * | 2017-12-14 | 2021-05-04 | 汤臣倍健股份有限公司 | Health composition and health food with sleep improving and/or antidepressant effects |
| CN109125617A (en) * | 2018-09-30 | 2019-01-04 | 昭通市天麻研究院 | A kind of Rhizoma Gastrodiae composition being effectively improved sleep and preparation method, preparation and application |
| CN114081175A (en) * | 2020-08-24 | 2022-02-25 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of sleep improvement product |
| CN113749253A (en) * | 2021-09-24 | 2021-12-07 | 李红光 | Food with functions of improving sleep and resisting depression |
| CN114668148B (en) * | 2022-03-31 | 2023-08-15 | 山东金胜生物科技有限公司 | Health care composition with effects of soothing nerves and aiding sleep as well as preparation method, health care product and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001187742A (en) * | 1999-12-28 | 2001-07-10 | Eag Kk | Testosteron-5-alfa-reductase inhibitor |
| CN1695492A (en) * | 2004-05-10 | 2005-11-16 | 沙大年 | Health food for stabilizing and adjusting blood pressure and improving sleep, and preparation method |
| CN1850064A (en) * | 2006-02-26 | 2006-10-25 | 郭凌云 | Preparation for relieving stress symptom |
| JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
| CN102030835A (en) * | 2010-11-03 | 2011-04-27 | 北京佗林医药科技有限公司 | Radix Morindae officinalis extract, preparation method and applications thereof |
| CN102423443A (en) * | 2011-12-27 | 2012-04-25 | 峨眉山天梁星制药有限公司 | Double-formula medicine used for treating insomnia, and preparation method thereof |
| CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
| CN107456531A (en) * | 2017-09-12 | 2017-12-12 | 江苏德和生物科技有限公司 | A kind of pharmaceutical composition, preparation and application that can improve sleep |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902569B (en) * | 2016-05-26 | 2019-07-09 | 吉林省中韩动物科学研究院 | Improve the composition and its preparation method and application of sleep disturbance |
| CN107997174B (en) * | 2017-12-14 | 2021-05-04 | 汤臣倍健股份有限公司 | Health composition and health food with sleep improving and/or antidepressant effects |
-
2017
- 2017-12-14 CN CN201711336886.7A patent/CN107997174B/en active Active
-
2018
- 2018-10-25 WO PCT/CN2018/111880 patent/WO2019114428A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001187742A (en) * | 1999-12-28 | 2001-07-10 | Eag Kk | Testosteron-5-alfa-reductase inhibitor |
| CN1695492A (en) * | 2004-05-10 | 2005-11-16 | 沙大年 | Health food for stabilizing and adjusting blood pressure and improving sleep, and preparation method |
| JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
| CN1850064A (en) * | 2006-02-26 | 2006-10-25 | 郭凌云 | Preparation for relieving stress symptom |
| CN102030835A (en) * | 2010-11-03 | 2011-04-27 | 北京佗林医药科技有限公司 | Radix Morindae officinalis extract, preparation method and applications thereof |
| CN102423443A (en) * | 2011-12-27 | 2012-04-25 | 峨眉山天梁星制药有限公司 | Double-formula medicine used for treating insomnia, and preparation method thereof |
| CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
| CN107456531A (en) * | 2017-09-12 | 2017-12-12 | 江苏德和生物科技有限公司 | A kind of pharmaceutical composition, preparation and application that can improve sleep |
Non-Patent Citations (1)
| Title |
|---|
| Anti-epilepsy Effect of Methanol Extract of Morinda officinalis Augments Pentylenetetrazol-Induced Convulsion Behaviors;Jin-sun Heo等;《Korean J. Plant Res.》;20131231;第26卷(第01期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019114428A1 (en) | 2019-06-20 |
| CN107997174A (en) | 2018-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107997174B (en) | Health composition and health food with sleep improving and/or antidepressant effects | |
| CN108671140B (en) | Composition for improving sleep and application thereof | |
| TW200904461A (en) | A pharmaceutical composition for treating depression and method for preparation thereof | |
| WO2009070915A1 (en) | Pharmaceutical compositions for treating depression and anxiety | |
| CN104069335A (en) | Medicine composition capable of improving sleep quality and preparation method of medicine composition as well as application of medicine composition | |
| CN115429864B (en) | Traditional Chinese medicine composition for treating depression | |
| WO2009070924A1 (en) | Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression | |
| KR20100106324A (en) | Antimelancholic medicine prepared with jujube camp material | |
| CN111840394B (en) | Pharmaceutical composition for insomnia and preparation method thereof | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| TWI706785B (en) | Composition for tranquilizing the nerves and aiding sleep and its preparation method and application | |
| CN116173177A (en) | Pharmaceutical composition for continuously improving male sexual function and preparation method thereof | |
| CN110269897B (en) | Composition for resisting fatigue and improving sleep and application thereof | |
| CN100450532C (en) | Chinese medicinal formulation for treating children's hyperkinetic syndrome | |
| CN110960632B (en) | Formula of sleep improving product and preparation method thereof | |
| CN114028514A (en) | Wolfberry fruit medicinal and edible dual-purpose composition with memory improving effect and preparation method and application thereof | |
| CN109380728B (en) | Composition and health food with auxiliary blood pressure lowering effect | |
| CN104338017B (en) | Pharmaceutical composition with sleep improvement effect, preparation method and application thereof | |
| CN114081175A (en) | Composition and application thereof in preparation of sleep improvement product | |
| CN105521306A (en) | Traditional Chinese medicine composition | |
| CN104984097A (en) | Chinese herba preparation for treating primary hypertension and application thereof | |
| CN112791166B (en) | Medicinal and edible composition for enhancing muscle performance and relieving exercise-induced fatigue | |
| CN110693936B (en) | Traditional Chinese medicine composition for reducing uric acid and preventing and treating hyperuricemia or gout and application thereof | |
| CN107595870A (en) | A kind of medicine composition capable of tonifying brain and soothing nerves, pharmaceutical preparation and application and preparation method | |
| KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |